Clinton O. Ogega
YOU?
Author Swipe
View article: mRNA-1273.251 and mRNA-1283.251 vaccines expressing SARS-CoV-2 variant LP.8.1 antigens broadly neutralize contemporary JN.1-lineage viruses
mRNA-1273.251 and mRNA-1283.251 vaccines expressing SARS-CoV-2 variant LP.8.1 antigens broadly neutralize contemporary JN.1-lineage viruses Open
The continued evolution of the SARS-CoV-2 Omicron JN.1 lineage has led to the emergence of antigenically distinct subvariants including KP.2, KP.3, XEC, and LP.8.1, which became the dominant strains in the Americas and Europe by mid-2025. …
View article: Multivalent mRNA-DTP vaccines are immunogenic and provide protection from Bordetella pertussis challenge in mice
Multivalent mRNA-DTP vaccines are immunogenic and provide protection from Bordetella pertussis challenge in mice Open
View article: Corrigendum: Convergent antibody responses are associated with broad neutralization of hepatitis C virus
Corrigendum: Convergent antibody responses are associated with broad neutralization of hepatitis C virus Open
[This corrects the article DOI: 10.3389/fimmu.2023.1135841.].
View article: Convergent antibody responses are associated with broad neutralization of hepatitis C virus
Convergent antibody responses are associated with broad neutralization of hepatitis C virus Open
Introduction Early development of broadly neutralizing antibodies (bNAbs) targeting the hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance of infection, so induction of bNAbs is a major goal of HCV va…
View article: B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection
B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection Open
Antibodies targeting the hepatitis C virus (HCV) envelope glycoprotein E2 are associated with delayed disease progression, and these antibodies can also facilitate spontaneous clearance of infection in some individuals. However, many infec…
View article: Convergent antibody responses associated with broad neutralization of hepatitis C virus and clearance of infection
Convergent antibody responses associated with broad neutralization of hepatitis C virus and clearance of infection Open
Early development of broadly neutralizing antibodies (bNAbs) targeting the hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance of infection, so induction of bNAbs is a major goal of HCV vaccine develop…
View article: Durable SARS-CoV-2 B cell immunity after mild or severe disease
Durable SARS-CoV-2 B cell immunity after mild or severe disease Open
Most SARS-CoV-2-infected individuals develop S-RBD specific, class-switched rMBCs that resemble germinal center derived B cells induced by effective vaccination against other pathogens, providing evidence for durable B cell mediated immuni…
View article: Durable SARS-CoV-2 B cell immunity after mild or severe disease
Durable SARS-CoV-2 B cell immunity after mild or severe disease Open
Multiple studies have shown loss of SARS-CoV-2 specific antibodies over time after infection, raising concern that humoral immunity against the virus is not durable. If immunity wanes quickly, millions of people may be at risk for reinfect…
View article: Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2
Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2 Open
Worldwide, more than 70 million people are infected with hepatitis C virus (HCV), which is a leading cause of hepatocellular carcinoma and liver transplantation. Despite the development of potent direct acting antivirals (DAAs) for HCV tre…